Würzburg Dynamics completes ￥120M+ Series B financing, solidifying its leading position in intelligent soft-tissue interventional surgical robotics

On December 27, 2025, Würzburg Dynamics celebrated its sixth registration anniversary and officially announced the completion of a Series B financing round exceeding 120 million. The round was largely finalized in April 2025 and jointly led by Guangzhou Jinkong Fund and Tianhe Investment Funds, with follow-on investments from Guangzhou Hedigong Investment, Shanghai Angel Group, NWPU Venture Capital, Wenzhou Oujiangkou Investment, and existing shareholder 3E Bioventures. Amid a tightening financing environment in recent years, the successful closure of another substantial funding round fully demonstrates the capital market's high recognition of Würzburg Dynamics' technological approach, clinical value, and commercialization capabilities. It also injects robust financial momentum to accelerate product iteration, expand Chinese and international markets, and achieve resilient, cycle-resistant growth.

Würzburg Dynamics is led by a national-level expert under China's Major Talent Program and founded by a team of returned Ph.D. holders with prior experience at globally renowned institutions such as Siemens Germany, Philips China, the Max Planck Society, Heidelberg University, and the University of Bern. It stands as the first company in China to simultaneously master dual-technology pathways for surgical robotics based on intraoperative CT and intraoperative ultrasound.

Würzburg Dynamics' products enable intelligent soft-tissue interventional surgery with diverse application scenarios. Beyond CT and ultrasound, they are also compatible with cross-platform imaging data such as CBCT and OBCT, covering a wide range of procedures including puncture biopsy, drainage, cryoablation, microwave ablation, radiofrequency ablation, laser ablation, nanoknife ablation, particle implantation, laparoscopic resection localization, percutaneous nephrolithotomy, targeted drug delivery, and biliary/pancreatic/splenic puncture. This transforms traditional qualitative operations, which heavily rely on surgeon experience and "hand feel," into a quantitative process grounded in multi-dimensional imaging data, geometric parameters, and AI models—providing foundational technological support for the evolution of interventional surgery from digitalization to intelligence.

Since obtaining National Class III Medical Device Registration in June last year for its intraoperative CT-based robotic system targeting lung and abdominal solid organ interventions, the system has been deployed in nearly one hundred hospitals across China, with several single centers performing nearly one hundred procedures per month on average. It has achieved "single-needle accuracy" in complex scenarios such as challenging lesions, multiple nodules, innovative ablation methods, and difficult access establishment, significantly reducing the number of puncture attempts and operation time. To date, no serious complications have been reported, and its clinical adaptability and safety have received broad recognition.

In terms of new product development and global expansion, Würzburg Dynamics' intelligent renal interventional surgical robot, developed based on the intraoperative ultrasound technology pathway, has already passed China's Special Review for Innovative Medical Devices and entered the innovation channel. Würzburg Dynamics is now fully advancing its CE registration process. As one of the few products in China within the same field to target overseas markets, it holds the potential to become the world's first intelligent surgical robot for renal interventions. This forward-looking global strategy reflects Würzburg Dynamics' differentiated core competitive advantage.

Würzburg Dynamics has established a clear global synergistic development model of "China-based validation and overseas expansion." While consolidating its market advantages in China, the company actively collaborates with leading global medical enterprises and specialized segment leaders to build its international ecosystem. Concurrently, it is advancing the domestic substitution of key consumables in China, aiming to break the technological monopoly held by overseas manufacturers in core areas of surgical robotics. This strategy aligns with national policy directives, reduces clinical costs, and enhances clinical usability and accessibility.

In the long term, intelligence represents the core direction for the development of surgical robotics. Würzburg Dynamics is driving the transformation of interventional surgery from "experience-driven" to "quantitative decision-making," and upgrading from "digital documentation" to "intelligent closed-loop management" through its interdisciplinary team and the continuous iteration of multiple product pipelines. This steady progression from a "precision tool" to an "intelligent surgical partner" further solidifies Würzburg Dynamics' leading position in the field of intelligent soft-tissue interventional surgical robotics.